Login to Your Account



Chasing Benlysta

Immunomedics, UCB Launch Epratuzumab SLE Phase III

By Tom Wall


Wednesday, December 15, 2010
Partners Immunomedics Inc. and UCB SA have launched two Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE), the most common form of lupus, a chronic and potentially fatal autoimmune disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription